These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28385415)

  • 1. Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions.
    Jabbour RJ; Tanaka A; Capranzano P; Cortese B; Lesiak M; Testa L; Gatto P; Suarez de Lezo J; Mattesini A; Geraci S; Ielasi A; Diletti R; Capodanno D; Buccheri D; Iwanczyk S; Bedogni F; Tchetche D; Di Mario C; Caramanno G; Van Mieghem NM; Tamburino C; Colombo A; Latib A
    JACC Cardiovasc Interv; 2017 Apr; 10(7):743-745. PubMed ID: 28385415
    [No Abstract]   [Full Text] [Related]  

  • 2. The future of bioresorbable vascular scaffolds: niche or workhorse devices?
    Lahoud R; Ellis S
    Coron Artery Dis; 2017 Sep; 28(6):449-451. PubMed ID: 28644214
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
    Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymeric bioresorbable coronary scaffolds: the hype is over, but the dream lives on.
    Pyxaras SA; Wijns W
    EuroIntervention; 2018 Jan; 13(13):1506-1509. PubMed ID: 29345240
    [No Abstract]   [Full Text] [Related]  

  • 5. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds.
    Anadol R; Schnitzler K; Lorenz L; Weissner M; Ullrich H; Polimeni A; Münzel T; Gori T
    BMC Cardiovasc Disord; 2018 May; 18(1):92. PubMed ID: 29743023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away?
    de Pommereau A; de Hemptinne Q; Varenne O; Picard F
    Arch Cardiovasc Dis; 2018 Apr; 111(4):229-232. PubMed ID: 29678390
    [No Abstract]   [Full Text] [Related]  

  • 7. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
    Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
    JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease.
    Testa L; Latib A; Montone RA; Colombo A; Bedogni F
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry.
    Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why Bioresorbable Vascular Scaffold Should Be Approved for Marketing in the United States.
    Waksman R
    Cardiovasc Revasc Med; 2015; 16(7):379-80. PubMed ID: 26573413
    [No Abstract]   [Full Text] [Related]  

  • 12. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Illustration of the Resorption Process Between 2 Different Overlapping Bioresorbable Scaffolds.
    Tanaka A; Jabbour RJ; Kawamoto H; Latib A; Colombo A
    JACC Cardiovasc Imaging; 2016 Dec; 9(12):1469-1470. PubMed ID: 27085427
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioresorbable vascular scaffolds for left main lesions; a novel strategy to overcome limitations.
    Miyazaki T; Panoulas VF; Sato K; Naganuma T; Latib A; Colombo A
    Int J Cardiol; 2014 Jul; 175(1):e11-3. PubMed ID: 24845788
    [No Abstract]   [Full Text] [Related]  

  • 17. Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry.
    Longo G; Granata F; Capodanno D; Ohno Y; Tamburino CI; Capranzano P; La Manna A; Francaviglia B; Gargiulo G; Tamburino C
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1150-61. PubMed ID: 25573598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions.
    Fam JM; Ishibashi Y; Felix C; Zhang BC; Diletti R; van Mieghem N; Regar E; van Domburg R; Onuma Y; van Geuns RJ
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1863-1871. PubMed ID: 28685314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyphering the mechanism of late failure of bioresorbable vascular scaffolds in percutaneous coronary intervention of the left main coronary artery.
    Gargiulo G; Longo G; Capodanno D; Francaviglia B; Capranzano P; Tamburino C
    JACC Cardiovasc Interv; 2015 May; 8(6):e95-e97. PubMed ID: 25999117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.